Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

BACKGROUND: The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in only approximately 40% of patients and the impact of baseline clinical factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ang, Joo Ern, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, Greve, Jacques De, Oza, Amit M., Banerjee, Susana, Rhoda Molife, L., Gore, Martin E., Kaye, Stan B., Yap, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564551/
https://www.ncbi.nlm.nih.gov/pubmed/28454085
http://dx.doi.org/10.18632/oncotarget.17005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564551/
https://www.ncbi.nlm.nih.gov/pubmed/28454085
http://dx.doi.org/10.18632/oncotarget.17005

Ejemplares similares